{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-024468","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2022-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.514589+00:00","generated_at":"2026-06-27T06:59:36.727388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ironwood Q4/FY2021: LINZESS blockbuster >$1B; total revenue $414M; pipeline advances","bullets":["FY2021 total revenue $414M (driven by $400M LINZESS collab revenue); GAAP net income $528M (incl $338M tax benefit).","Adjusted EBITDA $234M; year-end cash $620M.","Non-GAAP diluted EPS $1.16 vs $0.79 in FY2020; Q4 Non-GAAP EPS $0.27.","Initiated clinical studies for IW-3300 (visceral pain) and CNP-104 (primary biliary cholangitis).","LINZESS U.S. net sales exceeded $1B in 2021, achieving blockbuster status."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-024468","json":"https://secwatch.observer/filing/0001104659-22-024468.json","markdown":"https://secwatch.observer/filing/0001104659-22-024468.md","text":"https://secwatch.observer/filing/0001104659-22-024468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922024468/0001104659-22-024468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465922024468/tm226866d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:59:36.727388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}